| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7.0M | — | +27.6% |
| SG&A Expense | $1.7M | — | -16.1% |
| Operating Income | -$8.6M | — | -15.9% |
| Net Income | -$8.2M | — | -12.2% |
| EPS (Basic) | -$1.26 | — | -500.0% |
| EPS (Diluted) | -$1.26 | — | -500.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $63.8M | +943.3% | +662.9% |
| Short-term Investments | $34K | +0.0% | +2.1% |
| Current Assets | $65.6M | +614.5% | +380.8% |
| Total Assets | $67.4M | +634.1% | +394.0% |
| Current Liabilities | $6.6M | -36.5% | +63.1% |
| Total Liabilities | $6.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.4M | — | -151.3% |
| Financing Cash Flow | $70.1M | — | — |
| +60.3% |
| Stockholders' Equity | $60.7M | +4924.2% | +541.0% |